The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preclinical evaluation of LCK as a novel therapeutic target in YAP-activated and FGFR2-altered cholangiocarcinoma.
 
Caitlin Conboy
No Relationships to Disclose
 
Jennifer Yonkus
No Relationships to Disclose
 
EeeLN Buckarma
No Relationships to Disclose
 
Dong-Gi Mun
No Relationships to Disclose
 
Nathan Werneburg
No Relationships to Disclose
 
Ryan Watkins
No Relationships to Disclose
 
Yi Guo
No Relationships to Disclose
 
Juan Wang
No Relationships to Disclose
 
Daniel O'Brien
No Relationships to Disclose
 
Rogier Buijsman
Employment - Netherlands Translational Research Center
Stock and Other Ownership Interests - Netherlands Translational Research Center
Patents, Royalties, Other Intellectual Property - Netherlands Translational Research Center
 
Diep Vu
Employment - Netherlands Translational Research Center
 
Jos De Man
Employment - Netherlands Translational Research Center
 
Sumera Ilyas
Consulting or Advisory Role - AstraZeneca
 
Mark J. Truty
No Relationships to Disclose
 
Mitesh J. Borad
Stock and Other Ownership Interests - AVEO; Gilead Sciences; Intercept Pharmaceuticals; Spectrum Pharmaceuticals
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); De Novo Pharmaceuticals; Exelixis; Fujifilm (Inst); G1 Therapeutics; Genentech; Halozyme (Inst); Immunovative Therapies; Imvax; Inspyr Therapeutics; Insys Therapeutics (Inst); Klus Pharma; Lynx Group; Merck; Novartis (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Western Oncolytics
Research Funding - Adaptimmune (Inst); Agios (Inst); ARIAD (Inst); AstraZeneca (Inst); Basilea (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); Merck Serono (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); RedHill Biopharma (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene
 
Akhilesh Pandey
No Relationships to Disclose
 
Gregory J. Gores
Honoraria - Sagimet Biosciences
 
Rory L. Smoot
Consulting or Advisory Role - AstraZeneca